QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone31-77-355-6600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.50 billion
Profitability
Miscellaneous
Employees4,952
Next Earnings Date2/3/2020 (Estimated)
OptionableOptionable
Qiagen (NYSE:QGEN) Frequently Asked Questions
What is Qiagen's stock symbol?
Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."
How were Qiagen's earnings last quarter?
Qiagen NV (NYSE:QGEN) posted its quarterly earnings results on Wednesday, October, 30th. The company reported $0.36 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.35 by $0.01. The firm had revenue of $382.70 million for the quarter, compared to the consensus estimate of $382.98 million. Qiagen had a negative net margin of 1.68% and a positive return on equity of 12.24%. The business's revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 earnings per share. View Qiagen's Earnings History.
When is Qiagen's next earnings date?
What guidance has Qiagen issued on next quarter's earnings?
Qiagen updated its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion.
What price target have analysts set for QGEN?
17 brokerages have issued 1 year price objectives for Qiagen's stock. Their forecasts range from $31.00 to $42.00. On average, they anticipate Qiagen's stock price to reach $35.86 in the next year. This suggests that the stock has a possible downside of 12.9%. View Analyst Price Targets for Qiagen.
What is the consensus analysts' recommendation for Qiagen?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen.
Has Qiagen been receiving favorable news coverage?
Media stories about QGEN stock have been trending very negative on Monday, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Qiagen earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Qiagen.
Are investors shorting Qiagen?
Qiagen saw a increase in short interest in October. As of October 15th, there was short interest totalling 4,010,000 shares, an increase of 13.3% from the September 15th total of 3,540,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 1.9% of the company's shares are sold short. View Qiagen's Current Options Chain.
Who are some of Qiagen's key competitors?
Some companies that are related to Qiagen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), BioNTech (BNTX), Spark Therapeutics (ONCE), Repligen (RGEN), bluebird bio (BLUE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Crispr Therapeutics (CRSP).
What other stocks do shareholders of Qiagen own?
Who are Qiagen's key executives?
Qiagen's management team includes the folowing people:
- Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
- Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
- Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
- Mr. John Gilardi, VP of Corp. Communications & Investor Relations
- Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP
Who are Qiagen's major shareholders?
Qiagen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (5.55%), Hardman Johnston Global Advisors LLC (1.77%), First Trust Advisors LP (0.68%), Sycomore Asset Management (0.63%), Russell Investments Group Ltd. (0.22%) and Sector Gamma AS (0.21%).
Which major investors are selling Qiagen stock?
QGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Assenagon Asset Management S.A., Hardman Johnston Global Advisors LLC, Exane Asset Management, Zurcher Kantonalbank Zurich Cantonalbank, Rhumbline Advisers, Crossmark Global Holdings Inc. and First Bank & Trust.
Which major investors are buying Qiagen stock?
QGEN stock was bought by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Massachusetts Financial Services Co. MA, Fisher Asset Management LLC, SG Americas Securities LLC, Sector Gamma AS, Russell Investments Group Ltd., Brinker Capital Inc. and Stephens Investment Management Group LLC.
How do I buy shares of Qiagen?
Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Qiagen's stock price today?
One share of QGEN stock can currently be purchased for approximately $41.16.
How big of a company is Qiagen?
Qiagen has a market capitalization of $9.28 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.
What is Qiagen's official website?
How can I contact Qiagen?
Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]
MarketBeat Community Rating for Qiagen (NYSE QGEN)
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
